J Pediatr Pharmacol Ther. 2017 May-Jun;22(3):176-185. doi: 10.5863/1551-6776-22.3.176.
Abstract
Despite its controversial nature, the use of medical marijuana and cannabis-derived medicinal products grows more popular with each passing year. As of November 2016, over 40 states have passed legislation regarding the use of either medical marijuana or cannabidiol products. Many providers have started encountering patients experimenting with cannabis products for a wide range of conditions. While the debate continues regarding these agents for both medicinal and recreational use in the general population, special consideration needs to be made for pediatric use. This review will deliver the history of marijuana use and legislation in the United States in addition to the currently available medical literature to equip pediatric health care providers with resources to provide patients and their parents the best recommendation for safe and appropriate use of cannabis-containing compounds.
KEYWORDS:
CBD, cannabidiol; cannabis; epilepsy; pediatrics; pharmacy
- PMID: 28638299
- PMCID: PMC5473390
- DOI: 10.5863/1551-6776-22.3.176
-
Conflict of interest statement
Disclosures The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. Of note, both Augusta University (ClinicalTrials.gov Identifier: NCT02397863) and the University of Florida (ClinicalTrials.gov Identifier: NCT02461706) are sponsors of expanded access clinical trials of cannabidiol and drug-resistant epilepsy in children.
